Biochemist Joanne Lemieux worked with three other U of A researchers on a new study showing that a drug that cures deadly peritonitis in cats also works well enough against the coronavirus that causes COVID-19 to fast-track it into human clinical trials. (Photo: Supplied)
Fast-tracked research leads to phase 1 clinical trials.
Researchers at the University of Alberta are preparing to launch clinical trials of a drug used to cure a deadly disease caused by a coronavirus in cats that they expect will also be effective as a treatment for humans against COVID-19.
“In just two months, our results have shown that the drug is effective at inhibiting viral replication in cells with SARS-CoV-2,” said Joanne Lemieux, a professor of biochemistry in the Faculty of Medicine & Dentistry.
“This drug is very likely to work in humans, so we’re encouraged that it will be an effective antiviral treatment for COVID-19 patients.”
The drug is a protease inhibitor that interferes with the virus’s ability to replicate, thus ending an infection. Proteases are key to many body functions and are common targets for drugs to treat everything from high blood pressure to cancer and HIV.
First studied by U of A chemist John Vederas and biochemist Michael James following the 2003 outbreak of severe acute respiratory syndrome (SARS), the protease inhibitor was further developed by veterinary researchers who showed it cures a disease that is fatal in cats.
The work to test the drug against the coronavirus that causes COVID-19 was a co-operative effort between four U of A laboratories, run by Lemieux, Vederas, biochemistry professor Howard Young and the founding director of the Li Ka Shing Institute of Virology, Lorne Tyrrell. Some of the experiments were carried out by the Stanford Synchrotron Radiation Lightsource Structural Molecular Biology program.
“There’s a rule with COVID research that all results need to be made public immediately,” Lemieux said, which is why they were posted before being peer-reviewed.
She said interest in the work is high, with the paper being accessed thousands of times as soon as it was posted.
Lemieux explained that Vederas synthesized the compounds, and Tyrrell tested them against the SARS-CoV-2 virus in test tubes and in human cell lines. The Young and Lemieux groups then revealed the crystal structure of the drug as it binds with the protein.
”We determined the three-dimensional shape of the protease with the drug in the active site pocket, showing the mechanism of inhibition,” she said. “This will allow us to develop even more effective drugs.”
Lemieux said she will continue to test modifications of the inhibitor to make it an even better fit inside the virus.
But she said the current drug shows enough antiviral action against SARS-CoV-2 to proceed immediately to clinical trials.
“Typically for a drug to go into clinical trials, it has to be confirmed in the lab and then tested in animal models,” Lemieux said. “Because this drug has already been used to treat cats with coronavirus, and it’s effective with little to no toxicity, it’s already passed those stages and this allows us to move forward.”
“Because of the strong data that we and others have gathered we’re pursuing clinical trials for this drug as an antiviral for COVID-19.”
The researchers have established a collaboration with Anivive Life Sciences, a veterinary medicine company that is developing the drug for cats, to produce the quality and quantity of drug needed for human clinical trials. Lemieux said it will likely be tested in Alberta in combination with other promising antivirals such as remdesivir, the first treatment approved for conditional use in some countries including the United States and Canada.
The Latest Updates from Bing News & Google News
Go deeper with Bing News on:
- Scientists identify ‘nanobody’ with capacity to block SARS-CoV-2 from entering human cellson September 5, 2020 at 12:06 pm
To fight against Covid-19, scientists have identified a small neutralising antibody, a so-called nanobody, that has the capacity to block SARS-CoV-2 from entering human cells. The study, published in ...
- Roche to launch SARS-CoV-2 Rapid Antigen Test in countries accepting CE mark, allowing fast triage decisions at point of careon September 4, 2020 at 5:29 pm
Antigen test reliably and quickly triages people suspected of SARS-CoV-2, with results ready in 15 minutes, allowing informed treatment decisions - Antigen test accurately screens individuals with ...
- NanoViricides is Developing Drugs Against SARS-CoV-2 with an Integrated Approach to Combat COVID-19, as Reported at The LD 500 Virtual Conferenceon September 4, 2020 at 7:32 am
(NYSE American: NNVC) (the "Company") a global leader in the development of highly effective antiviral therapies based on a novel nanomedicines platform, today reported on the Presentation by Anil R.
- An alpaca nanobody neutralizes SARS-CoV-2 by blocking receptor interactionon September 4, 2020 at 2:23 am
Here, Hanke et al. immunize an alpaca with SARS-CoV-2 spike protein domains and identify a nanobody that binds the receptor binding domain of spike in both the up and down conformations and sterically ...
- Roche receives FDA Emergency Use Authorization for the cobas SARS-CoV-2 & Influenza A/B Test for use on the cobas 6800/8800 Systemson September 3, 2020 at 10:00 pm
First commercial test for fully automated high throughput systems to detect and differentiate SARS-CoV-2, influenza A virus and/or influenza B virus with a single sample As ...
Go deeper with Google Headlines on:
Go deeper with Bing News on:
- As Africa's COVID-19 cases rise, faith is put to the teston September 5, 2020 at 2:25 pm
KAMPALA, Uganda (AP) — The COVID-19 pandemic is testing the patience of some religious leaders across Africa who worry they will lose followers, and funding, as restrictions on gatherings continue.
- FDA rejects drug touted as possible COVID-19 ‘cure’ by MyPillow CEOon September 5, 2020 at 10:36 am
The FDA on Friday gave its safety thumbs down to Oleandrin — the extract the MyPillow CEO has pushed as a possible coronavirus cure. Oleandrin, could not “reasonably be expected to be ...
- Covid-19 is crashing college parties. That could send the students back home.on September 5, 2020 at 2:00 am
A rapid uptick in cases is pushing UB to the verge of a shutdown, the same week that a different SUNY school had to make that decision.
- DOH exec: COVID-19 treatment improved, mortality rate down to 1.6%on September 4, 2020 at 9:46 pm
A Department of Health official said Saturday that the Philippine clinical management and treatment modalities for COVID-19 have greatly improved overtime, pushing case mortality rate from 5 down to 1 ...
- ‘Hopefully This Is Going To Lead To A Cure’: Long Beach Man Takes Part In COVID-19 Vaccine Trialon September 4, 2020 at 6:06 pm
Jorge Vega, a Long Beach resident, became the first person to get vaccinated in the third phase of a research study on a COVID-19 vaccine developed by Oxford University and AstraZeneca. “I’m very ...